Allied Healthcare Group (ASX: AHZ) has been granted a trading halt by the ASX today as it prepares to release an announcement to the market regarding a capital raising, with the company in pre-open.
The company’s tissue engineering and regenerative medicine division Celxcel has been busy confirming the broader applications of its CardioCel® cardiovascular patch.
Celxcel has successfully implanted the patch during a double valve leaflet reconstruction.
Importantly, positive results in the study opens up further commercial discussion opportunities for Allied Healthcare Group and Celxcel on the potential applications of CardioCel®.
The halt will last until the earlier of an announcement being made available to the market, or the opening of trade on Friday 16 February.